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ABSTRACT: A new series of N-aryl-N′-3,4-dihydro-2,2-dimethyl-2H-1-
benzopyran-4-yl)ureas bearing an alkoxycarbonylamino group at the
6-position were synthesized and examined as putative anticancer agents
targeting sirtuins in glioma cells. On the basis of computational docking
combined to in vitro sirtuin 1/2 inhibition assays, we selected compound
18 [R/S-N-3-cyanophenyl-N′-(6-tert-butoxycarbonylamino-3,4-dihydro-
2,2-dimethyl-2H-1-benzopyran-4-yl)urea] which displays a potent anti-
proliferative activity on various glioma cell types, assessed by quantitative
videomicroscopy, eventually triggering senescence. The impact on
normal glial cells was lower with a selectivity index of >10. Furthermore,
human U373 and Hs683 glioblastoma cell lines served to demonstrate
the inhibitory activity of 18 against histone deacetylase (HDAC) class III
sirtuins 1 and 2 (SIRT1/2) by quantifying acetylation levels of histone
and non-histone proteins. The translational potential of 18 was validated by an NCI-60 cell line screen and validation of growth
inhibition of drug resistant cancer cell models. Eventually, the anticancer potential of 18 was validated in 3D glioblastoma
spheroids and in vivo by zebraﬁsh xenografts. In summary, compound 18 is the ﬁrst representative of a new class of SIRT
inhibitors opening new perspectives in the medicinal chemistry of HDAC inhibitors.
■ INTRODUCTION
Glioblastomas are associated with dismal prognoses due to their
intrinsic resistance to proapoptotic stimuli,1 and temozolomide,
a generic compound, remains today the most eﬃcient chemo-
therapeutic agent to ﬁght glioblastoma once maximal surgery
and radiotherapy have already been performed.2 Consider-
ing the absence of chemotherapeutically active drugs against
glioblastoma, the reduced life expectancy of the patients, and
the speciﬁc molecular characteristics of this type of cancer, it
becomes increasingly clear that new compound groups and
molecular targets need to be investigated. Recently, histone
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deacetylase (HDAC) and sirtuin (SIRT) inhibitors (SIRTi) were
shown to trigger metabolic eﬀects in glioblastoma independently
or combined with temozolomide,3 allowing speculation about
the potential impact of SIRTi on this cancer type.
NAD+-dependent deacetylase class III of HDACs comprises a
family of seven members, namely, SIRT1−7, known to dea-
cetylate histones and other target proteins. Intracellular local-
ization characterizes the diﬀerent isoforms (SIRT1/2, nucleus or
cytoplasm; SIRT3−5, mitochondria; SIRT6, nucleus; SIRT7,
nucleolus) as well as substrate speciﬁcity: besides histones, many
transcriptional regulators and mitochondrial proteins are
deacetylated by SIRTs.4,5
SIRTs are emerging targets for the treatment of various
chronic diseases including cancer.6,7 Especially, both SIRT1 and
-2 have been reported to play a key role in the development of
cancer.8,9 Accordingly, ﬁrst inhibitors comprised compounds
resembling the physiological substrates such as NAD+ analogs
that were described as competitive SIRTi compounds that com-
pete with NAD+ for the NAD+-binding domain, thus inhibiting
enzymatic activity of multiple SIRTs. Such compounds showed
anticancer activity in B-cell chronic lymphoblastic leukemia or
prostate cancer.10 Suramin (1) (Figure 1), an adenosine receptor
antagonist, acts as a SIRTi by binding the C pocket, B pocket,
and partially the enzyme’s substrate-binding site.11 1 was shown
to possess anticancer potential in combination with cytotoxic
agents in xenografted prostate, lung, and breast cancer cells.12
Similarly, sirtinol (2) (Figure 1), a well described SIRT1 and -2
selective inhibitor, displays anticancer properties against various
cancer models.9,10 Although, most SIRTi compounds lack
selectivity against a speciﬁc isoform, EX-527 (3) (Figure 1)
was reported to inhibit SIRT1 but is less active against SIRT2 and
SIRT3.13 A combination treatment using 3 and other HDAC
inhibitors was found to induce apoptosis in acute myeloid
leukemia cells.10 The selective inhibition of SIRT2 by AGK2 (4)
(Figure 1)14 has been reported to induce anticancer eﬀects by
suppressing tumor cell growth and migration.15
Recently, some of our structural analogs of the ATP-sensitive
potassium(KATP) channel opener cromakalim (5), 6-halo-substituted
3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans (or 2,2-dimethylchro-
mans), bearing an arylurea or arylthiourea moiety at the 4-position
(6: X = F, Cl, Br), were described as potent inhibitors of glioma.
Here we synthesized a series of N-aryl-N′-3,4-dihydro-2,2-
dimethyl-2H-1-benzopyran-4-yl)ureas and thioureas bearing an
alkoxycarbonylamino group (“carbamate” group) at the 6-position
(6: X = NHCOOR) and investigated their anticancer eﬀects on
glial tumor cells (Figure 2). Our results show that compound 18
[R/S-N-3-cyanophenyl-N′-(6-tert-butoxycarbonylamino-3,4-dihy-
dro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea] inhibits SIRT1/2
activity associated with a potent antiproliferative activity on
glioblastoma cells while having a lower impact on normal glial
cells, thus demonstrating an excellent diﬀerential toxicity. For the
ﬁrst time, we document here the in vitro characterization of 18 as a
novel SIRT inhibitor and its in cellulo epigenetic eﬀect combined
with its anticancer potential in 2D and 3D cell culture. Our
results are validated in vivo by zebraﬁsh glioblastoma xenografts.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of the key intermediate 9 has been
previously described.16 The target compounds 10−28 were
Figure 1. Reference HDAC inhibitors.
Figure 2. Chemical structure of cromakalim (5) and general formula of
4-arylurea/arylthiourea-substituted 2,2-dimethylchromans (6) previ-
ously reported as KATP channel openers. Compounds 7 and 8 are
examples of 2,2-dimethylchromans exerting antiproliferative activity
against glioma cell lines.
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prepared in good yields by reaction of 9 with the appropriate
monosubstituted phenyl isocyanate in methylene chloride at
room temperature (Scheme 1).
Starting from the N-3-cyanophenyl-substituted urea 18,
the corresponding N-3-aminomethyl-substituted analog 22 was
obtained after reduction of the cyano group using hydrogen gas
in the presence of Raney nickel0 (Scheme 2). On the other hand,
acid-catalyzed deprotection of the tert-butyl carbamate group of
18 provided the corresponding 6-amino-substituted chroman 33,
which by formylation gave access to the 6-formamido-substituted
analog 34 (Scheme 2).
Reduction of the nitro group of compound 19 into the amino-
substituted compound 23 was performed with iron powder in the
presence of ammonium chloride in ethanol/water 3:1 (Scheme 3).
The target compound 32 was obtained by reaction of the pre-
viously described compound 3117 with 3-cyanophenyl isocyanate
(Scheme 4).
All the compounds were crystallized from appropriate solvents
and characterized by 1H and 13CNMR. Their purity was assessed
by elemental analysis to obtain the ﬁnal materials with the
chemical purity required before pharmacological evaluations.
Growth Inhibitory Activity against Glioma Cells. The
in vitro eﬀects of the 2,2-dimethylchromans 10−28 and 32−37
on the growth of three human high-grade glioma cell lines,
i.e., U373 and T98G from astroglial origin and Hs683 from
oligodendroglial origin, were examined (Tables 1 and 2; see
Experimental Section for details). Moreover, the selective tox-
icity between normal astrocytes and glioma cells regarding in
vitro growth inhibition was also investigated for several com-
pounds listed in Table 1.
The 2,2-dimethylchroman compounds tested on glioma cells
were characterized by the presence of a variety of substituents
at the ortho, meta, or para position of the phenyl ring in the
arylurea or arylthiourea moiety located at the 4-position of the
benzopyran ring. Themonosubstitution was investigated in these
three positions with moderate to strong electron withdrawing
(halogen, CN, NO2, CF3) or electron donating (OCH3, NH2)
groups (Table 1). With a second set of compounds, the nature of
the substituent in the 6-position was also examined (Table 2).
Particular attention was paid to the progressive increase of the
steric hindrance of the “carbamate” moiety in this position.
From the data reported in Table 1, it was observed that for the
compounds bearing the same substituent on the phenyl ring, the
ortho position was generally found to be less favorable for growth
inhibitory activity on glioma cells than the meta and the para
positions (compare 10 versus 16 and 24; compare 11 versus 18
and 25; compare 13 versus 20 and 27). However, no general
trend can be formally deduced. The nitro group, for example, was
better tolerated in the ortho position than in the para position,
while the meta position remains the best choice for improved
activity against all tumor cell lines (see 12, 19, and 26).
It also appears that for growth inhibitory activity on glioma
cells, an electron withdrawing group was preferred to an electron
donating group (i.e., positive mesomeric eﬀect of OCH3 and
NH2), in particular in the meta and the para positions (compare
21 and 23 versus 15−20; compare 28 versus 24−27).
Taken as a whole, the two best compounds from Table 1 were
the 3-cyano and the 3-nitro-substituted arylurea compounds
18 and 19, with an equal potency compared to cisplatin in
these three tumor cell lines models, and 4-cyano-substituted
arylthiourea compound 30, previously described as an inhibitor
of insulin release.16 Interestingly, the reduction of the cyano
Scheme 1a
aReagents: (i) X-C6H4-NCO, CH2Cl2, rt, 75−85%.
Scheme 2a
aReagents: (i) 5 N HCl in EtOH, rt, 80% ; (ii) HCOOH, Ac2O, THF, rt., 80−85%; (iii) H2, Raney nickel0, EtOH, 65%.
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group of 18, which provides the corresponding aminomethyl-
substituted derivative 22, gave rise to a complete loss of biological
activity.
Results reported in Table 2 clearly indicated that the presence
of a bulky tert-butoxycarbonylamino group (see 18) was preferred
to less bulky “carbamate” moieties (see 35, 36, 37) or the absence
of a substituent (see 32). The introduction of an amino (33) or a
formamido group (34) was responsible for a complete loss of
growth inhibitory activity against the three tumor cell lines.
Finally, looking at the selectivity index deﬁned as the ratio
between the GI50 values on normal and tumor astrocytes, 18
Scheme 3a
aReagents: (i) Fe, NH4Cl, EtOH, H2O, 50%.
Scheme 4a
aReagents: (i) 3-cyanophenyl isocyanate, CH2Cl2, rt, 90−95%.
Table 1. In Vitro Growth Inhibitory Activity against Three Human Glioma Cell Lines and Determination of Cell Selectivity Using
Murine Normal Astrocytes (Modulation of the 4-Position)
in vitro IC50 (μM)
a,d
compd Y R U373 T98G Hs683 meand Selb,d AclogPc
10 O 2-Cl 59 ± 11 88 ± 24 34 ± 3 60 ± 27 - 4.65
11 O 2-CN 45 ± 8 67 ± 7 54 ± 5 55 ± 11 - 3.99
12 O 2-NO2 12 ± 1 22 ± 2 13 ± 1 16 ± 6 >10 4.20
13 O 2-CF3 >100 - - - - 4.86
14 O 2-OCH3 30 ± 1 39 ± 1 59 ± 4 43 ± 15 - 3.96
15 O 3-F 20 ± 1 26 ± 1 19 ± 2 22 ± 4 - 4.23
16e O 3-Cl 18 ± 2 20 ± 3 12 ± 3 17 ± 4 >12 4.65
17 O 3-Br 22 ± 1 26 ± 3 18 ± 1 22 ± 4 - 4.79
18e O 3-CN 6 ± 1 14 ± 1 4 ± 1 8 ± 5 >10 3.85
19 O 3-NO2 1 ± 1 7 ± 4 16 ± 2 8 ± 8 <5 4.04
20 O 3-CF3 9 ± 1 21 ± 2 9 ± 1 13 ± 7 <2 4.86
21 O 3-OCH3 30 ± 1 >100 37 ± 2 >56 - 3.97
22 O 3-CH2NH2 >100 >100 95 ± 4 >98 - 3.10
23 O 3-NH2 97 ± 2 >100 91 ± 5 >96 - 3.24
24e O 4-Cl 22 ± 1 26 ± 3 26 ± 3 25 ± 2 - 4.65
25e O 4-CN 10 ± 1 26 ± 1 18 ± 2 18 ± 8 >10 3.85
26 O 4-NO2 24 ± 1 26 ± 1 20 ± 1 23 ± 3 - 4.05
27 O 4-CF3 10 ± 1 15 ± 2 11 ± 1 12 ± 3 >10 4.86
28 O 4-OCH3 33 ± 1 49 ± 2 62 ± 9 48 ± 15 - 3.24
29e S 3-CN 19 ± 3 10 ± 2 26 ± 2 18 ± 8 <2 4.28
30e S 4-CN 7 ± 1 7 ± 1 7 ± 1 7 ± 1 - 4.28
cisplatin NAf NAf 4 ± 1 12 ± 4 4 ± 1 7 ± 3 NAf NAf
aIC50 values: concentration of drug responsible for the inhibition of 50% of the growth of the speciﬁed cell line after 72 h [mean ± SEM (n = 6
replicates)]. b“Sel” means the level of selectivity, i.e., IC50 values obtained on murine normal astrocytes (n = 3)/IC50 values obtained on human
tumor astrocytes (n = 3). cAclogP: calculated log P values according to the ALOGPS 2.1 software [VCCLAB, Virtual Computational Chemistry
Laboratory, http://www.vcclab.org, 2005]. d“-” = not determined. ePublished compounds in refs 16 and 56. fNA: not applicable.
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(with a selectivity index of >10) was identiﬁed as one of the most
promising compounds.
Biology. Therapeutic Potential of SIRT1 and -2 Target-
ing in Glioblastoma. Since the simultaneous inhibition of
SIRT1 and -2 has been shown to display promising anticancer
properties,8,18 we aimed to assess the therapeutic potential of the
pharmacological targeting of SIRT1 and -2 in glioblastoma. First,
we investigated basal SIRT1 and -2 protein expression levels in
U373 and Hs683 (Figure 3A). Results showed that Hs683 cells
expressed a high constitutive level of SIRT1 compared to U373
cell, whereas SIRT2 was expressed at higher levels in U373 cells.
Accordingly, we then knocked down SIRT1 in HS683 and
SIRT1 and SIRT2 in U373 using siRNAs (Figure 3B) and
followed their eﬀects on cell growth (Figure 3C) by videomicros-
copy over 72 h. Results suggested that a depletion of SIRT1 or -2
strongly reduced the proliferation of glioblastoma cells, thus
further validating SIRT1 and -2 as interesting pharmacological
targets.
Predicting SIRT1/2 Binding Aﬃnity of 2,2-Dimethyl-
chroman Derivatives. To combine the diﬀerential cytotox-
icity of our 2,2-dimethylchromans to their potential to inhibit
SIRT1/2 activities, we compared the binding aﬃnity of selected
2,2-dimethylchroman derivatives to known SIRTi including 2 as
a dual SIRT1/2 inhibitor, 3 (SIRT1 inhibitor), and 4 (SIRT2
inhibitor). First, derivatives were analyzed against the human
SIRT1 complex [Protein Data Bank (PDB) code 4I5I] and
SIRT2 complex (PDB code 4RMG) using AutoDock Vina19 as
described in “Experimental Section”. Brieﬂy, the SIRT1 and -2
complexes were divided into ligand and protein and then the
ligands were docked into the protein complexes. In silico docking
results are represented in Table 3 and Figure SI-1 in Supporting
Information.
Since compound 18 with the N-alkyl-N′-arylurea group in its
cis, trans low-energy conformation demonstrated best docking
aﬃnity against SIRT1/2 (Figure 4), a qualitative molecular
docking was then performed with compound 18 in comparison
to the SIRTi 4 and 2 against seven available experimental cocry-
stallized human SIRT2 complexes. The resulting lowest binding
aﬃnities were compared (Table 4A).20−23 Overall, compound 18
exhibited a similar aﬃnity to 2 but less than 4. In Figure 4A, the
lowest aﬃnity pose of compound 18 was selected as the likely
binding modes in the binding pocket of SIRT2 (PDB code
4RMG) where compound 18 formed a hydrogen bond with
the backbone carbonyl oxygen of Val233. In addition, similar
docking experiments were performed using compound 18 in
comparison with the SIRTi 3 and 2 against six available experi-
mental cocrystallized human SIRT1 complexes (Table 4B).24−27
Compound 18 exhibited better binding aﬃnities than 3 and 2.
The lowest binding aﬃnity pose of compound 18 was selected as
the likely binding mode in the binding pocket of SIRT1 protein
(PDB code 4I5I) where compound 18 formed two hydrogen
bonds with the backbone nitrogen of Ala262 and the Nδ atom of
His363 (Figure 4B).
Compound 18 Acts as a SIRT1/2 Inhibitor. Considering
the proﬁciency of various HDAC inhibitors to impair glioblas-
toma cell proliferation3,28 and the strong eﬀect of the depletion of
SIRT1 and -2 on glioblastoma cell growth, we then validated the
potential of various 2,2-dimethylchromans selected based on our
computational docking results to inhibit SIRT activities in vitro
(Table 5). In agreement with our docking data, compound 18
markedly inhibited both SIRT1 (IC50 = 6.2 ± 1.7 μM) and
SIRT2 (IC50 = 4.2 ± 1.6 μM) activities within a concentration
range comparable to 1 used as a positive control, even though 1
showed higher selectivity for SIRT1 (2.8 ± 0.3 μM) versus
SIRT2 (13 ± 1 μM), whereas other derivatives performed less
well or not at all.
Collectively, these data pointed out compound 18 as a good
drug candidate for further investigation. First, we evaluated the
selectivity of 18 by testing its activity against total in vitro HDAC
activities (Figure 5A) as well as against the in vitro activity of
various nonsirtuin HDAC isoenzymes (Figure 5B). Results
showed only residual inhibition of total HDAC activity, whereas
increasing concentrations (0.1−100 μM) of 18 did not sig-
niﬁcantly impact HDAC 1, 2, 3, 8, 6, 10, and 11 activities. There-
fore, compound 18 appeared essentially as a potent inhibitor
of SIRT1/2 but not of SIRT3. Presently, we cannot exclude
that 18 also targets other SIRT isoforms insofar expressed by
glioblastoma.
To validate in vitro results, 18was then investigated on human
U373 and Hs683 glioblastoma to assess in cellulo eﬀects of SIRT
inhibition on acetylation levels of histone and non-histone pro-
teins. Cells were treated for 24 h at concentrations of 1−10 μM
Table 2. In Vitro Growth Inhibitory Activity against Three Human Glioma Cell Lines (Modulation of the 6-Position)
in vitro IC50 (μM)
a
compd R U373 T98G Hs683 mean AclogPb
32 H 38 ± 2 32 ± 5 31 ± 5 34 ± 3 2.52
33 NH2 >100 >100 >100 >100 2.52
34 NHCHO >100 >100 >100 >100 2.41
35c NHCOOCH3 45 ± 10 56 ± 7 84 ± 8 60 ± 20 2.82
36c NHCOOC2H5 38 ± 2 46 ± 4 15 ± 2 33 ± 16 3.19
37c NHCOOCH(CH3)2 8 ± 1 40 ± 5 45 ± 6 31 ± 20 3.53
18c NHCOOC(CH3)3 6 ± 1 14 ± 1 4 ± 1 8 ± 5 3.85
aIC50 values: concentration of drug responsible for the inhibition of 50% of the growth of the speciﬁed cell line after 72 h [mean ± SEM (n = 6
replicates)]. bAclogP: calculated log P values according to the ALOGPS 2.1 software [VCCLAB, Virtual Computational Chemistry Laboratory,
http://www.vcclab.org, 2005]. cPublished compounds in ref 56.
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18 compared to the pan-HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA, 38; 2 μM) used as a positive control
(Figures 1 and 6). We observed a concentration-dependent
increase of α-tubulin, a well-known protein substrate for
SIRT2,29 and histone H4 acetylation starting at 5 μM in U373
cells and 1−2.5 μM in Hs683 cells, respectively. The diﬀerential
dose−response of protein acetylation observed in those two cell
lines after 18 exposure depending on the analyzed sirtuin
substrate could be explained by the constitutive SIRT1 and -2
protein expression levels observed in glioblastoma cell lines
(Figure 3A). Furthermore, 18 increased acetylation levels in
both lines for acetylated H4 and H3K56, reported to serve as
substrates for SIRT1 (Figure SI-2).
Furthermore, we compared the growth inhibitory activity
of 18 to reference SIRTi against U373 and Hs683 cell lines
(Table 6). MTT results highlighted 18 as a promising anticancer
drug as it had the most pronounced growth inhibitory potency
against glioblastoma cells, about 6 times compared to the SIRT1/
2 inhibitor 2 and about 20 and 6−14 times for the SIRT1 and
SIRT2 inhibitors 3 and 4, respectively.
Finally, we investigated the eﬀect of the depletion of SIRT1
or SIRT2 on the anticancer eﬀects of compound 18 in glio-
blastoma cells. Results demonstrated that the downregulation
of either one of these two HDAC enhanced the growth inhib-
itory properties of compound 18 on U373 and Hs683 cells
(Figure 7).
Figure 3. SIRT1/2 silencing decreases glioblastoma cell proliferation. (A) Constitutive SIRT1 and SIRT2 protein expression levels in U373 and Hs683
cell lines analyzed by Western blot. α-Tubulin was used as a loading control. (B, C) U373 and Hs683 cell lines were transfected with the indicated
siRNA. (B) SIRT1 and SIRT2 protein expression levels were analyzed 24 h post-transfection. β-Actin was used as loading control. (C) 24 h post-
transfection cell proliferation was monitored by time-lapse videomicroscopy. Graphs are representative of three independent experiments and
correspond to the mean ± SD of 16 pictures per well acquired in triplicate. Blots are representative of three independent experiments, and
quantiﬁcations are indicated under the blots.
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Compound 18 Does Not Exert Its Growth Inhibitory
Activity through Proapoptotic Eﬀects in Human Glio-
blastoma Cells.We then assessed the biological eﬀect of com-
pound 18 by using computer-assisted phase contrast microscopy
(quantitative videomicroscopy) to grossly analyze the way by
which compound 18 inhibits the growth of human U373 and
Hs683 glioma cell lines (Figure 8). Figure 8A shows that 10 μM
(i.e., approximately the GI50 value revealed by the MTT
colorimetric assay, Table 1) compound 18 decreased by ∼70%
the growth of the Hs683 cell line after 72 h of culture. While the
growth inhibitory eﬀects of 18 were pronounced on Hs683 cell
line growth, the 18-related growth inhibitory activity rather
corresponded to cytostatic than to cytotoxic eﬀects on these
Hs683 tumor cells as morphologically illustrated in Figure 8.
The deﬁnitions of the global growth and the global growth ratio
are provided in the legend of Figure 8. The same features were
observed on the U373 glioblastoma cells (Figure 8B). Remark-
ably, while U373 glioblastoma cells display certain levels of
resistance to proapoptotic stimuli,30 these U373 cells appear as
sensitive as Hs683 oligodendroglioma cells to the growth
inhibitory eﬀects of compound 18 (Table 1, Figure 8) with the
fact that Hs683 cells are sensitive to proapoptotic stimuli.30,31
The quantitative videomicroscopy-related analyses suggested
that compound 18 is cytostatic rather than cytotoxic in both
Hs683 and U373 glioma cell lines. We thus made use of ﬂow
cytometry analyses to investigate whether compound 18
induced, or not, signiﬁcant proapoptotic eﬀects in these two
glioma cell lines. The data obtained with 10 μM compound 18
indicated modest proapoptotic eﬀects in Hs683 and weak, if any,
eﬀects in U373 glioma cells (Figure SI-3). It is thus unlikely that
the growth inhibitory eﬀects observed at 10 μM for compound
18 (Table 1, Figure 8) could relate to cytotoxic proapoptotic
eﬀects, even if, as expected,30,31 Hs683 oligodendroglioma cells
are more prone to enter apoptosis than U373 glioblastoma cells.
Indeed, while both the MTT colorimetric assay and the quan-
titative videomicroscopy approach revealed that 10 μM com-
pound 18 inhibited by ≥50% the growth of both Hs683 and
U373 glioma cell lines (Table 1, Figure 8), ﬂow cytometry
analyses revealed that 10 μM compound 14 induced ∼25% and
<10% apoptosis in Hs683 and U373 glioma cells, respectively
(Figure SI-3). These results were conﬁrmed and generalized by
the absence of a signiﬁcant accumulation of cells in the sub G1
population (Figure SI-4) when cells were treated with various
SIRTi at the IC50 calculated from MTT assays (Table 6). Only 4
induced a modest increase of sub G1 population in both cell lines
as observed with the pan-non-sirtuin HDAC inhibitor 38 in
U373 cells.
Eﬀect of Compound 18 on Cell Cycle and Senescence.
Considering the strong eﬀect of 18 on glioblastoma cell growth,
we then investigated the eﬀect of various SIRTi compounds on
cell cycle distribution. As shown in Figure 9A, compound 18
induced an accumulation in G1 in both cell lines comparable to
the one observed with the SIRT1 inhibitor 3 as well as with the
SIRT1/2 inhibitor 2 and the pan-non-sirtuin inhibitor 38 in
Hs683 cells. In contrast, the SIRT2 inhibitor 4 triggered G2/M
accumulation in both cell lines as observed with 2 and 38 in U373
cells.
Irreversible cell cycle arrest may result in senescence induc-
tion.32 Therefore, we investigated whether sustained exposure
to subtoxic concentrations of compound 18 may promote
senescence-associated β-galactosidase (SA-β-gal) activity. As
shown in Figure 9B, the number of senescent cells, identiﬁed as
blue-stained cells, was markedly increased in 18-treated U373
cells (≅20%), whereas no blue-stained cells were detected in
untreated cells.
Compound 18 Inhibits Glioblastoma Cell Growth
in Vivo. Considering the drastic antiproliferative properties of
18 in vitro, we next investigated whether this compound could
also hamper the spheroid-forming capacity of glioblastoma
cells. Our results show that 5 and 10 μM compound 18 sig-
niﬁcantly reduced the surface area and volume of multicellular
tumor spheroids from glioma Hs683 (Figure 10A) and U373
(Figure SI-5) cell lines. The propensity of compound 18 to
reduce the 3D tumor-like growth of glioblastoma cells was also
conﬁrmed by decreased ATP levels in 18-treated tumor spheroid
glioblastoma cultures (Figures 10A and SI-5).
To further extend our evaluation of the growth inhibitory
capacities of 18 toward in vivo settings, we examined the ability of
18 to abrogate tumor development in a zebraﬁsh xenotrans-
plantation model. Fluorescently labeled tumor cells were pre-
treated for 30 (Figure SI-5) or 36 h (Figure 10B) with compound
18 and then injected into the yolk sacs of zebraﬁsh embryos.
Results revealed that the tumor-associated ﬂuorescence intensity
signal was drastically lowered in the 18-treated zebraﬁsh group
compared to the untreated control group for both glioblastoma
Hs683 and U373 cell lines. The capacity of 18 to impede tumor
formation in vivo validated our in vitro results and sustained the
potential anticancer activity of 18.
Compound 18 Is Active against a Broad Range of
Tumor Cell Lines Including Drug-Resistant Cancer Cells
Harboring Diﬀerent Resistance Mechanisms. Next, to
extend the anticancer potential of 18, Figure 11 (revealed with
the permission of the NCI) shows that the mean GI50 value of
compound 18 in the NCI-60 cell line panel is log10
GI50 = −5.52,
i.e.,∼3 μM, a concentration very close to the one we obtained on
the three Hs683, U373, and T98G glioma cell lines, i.e., 8±5 μM
(Table 1). Figure 11 further shows that compound 18 displays
similar growth inhibitory activity against a broad majority of the
NCI cell lines.
Table 3. In Silico Docking Scores of Selected Compounds
against Human SIRT1 and SIRT2a


















aBinding aﬃnity energy values (kcal/mol) for the indicated PDB
codes were calculated using AutoDock Vina (for more details see
Experimental Section). 2, 3, and 4 were used as reference inhibitors of
SIRT1/2, SIRT1, and SIRT2, respectively. “-” = not determined.
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Successful cancer therapy by chemotherapeutic agents but also
targeted small molecule inhibitors is frequently limited by drug
resistance mechanisms leading to treatment failure and recur-
rence. Resistance might be mediated by mutations in sensor
genes of DNA damage, like the tumor suppressor p5333 or
overexpression of pleiotropic eﬄux pumps for multiple drugs
causing a broad-scale multidrug resistance (MDR) phenotype.34
Hence we tested whether mutation of p53 or overexpression of
the major MDR proteins ABCB1 (P-glycoprotein) and ABCC1
(multidrug resistance protein 1, MRP1) signiﬁcantly reduces the
anticancer activity of 18 (Figure 12). Neither loss of p53 nor
overexpression of these ABC transporters resulted in a signiﬁcant
loss of activity against the investigated drug resistance models
(Table SI-1). In contrast, ABCB1 overexpression in SW1573
2R160 and KB-C-1 lines even resulted in a slight hypersensitivity
to 18 (Figure 12B and Figure 12D, respectively, and Table SI-1).
Additionally, an ovarian cancer cell model with acquired cisplatin
resistance (A2780cis) and a hydroxyurea-resistant HeLa deriva-
tive overexpressing ribonucleotide reductase model (KB-HU)35
were compared to their respective parental cell lines (Figure 12C
and Figure 12D, respectively). Also in these two cases, no sig-
niﬁcant impact of the resistance phenotype on the cytotoxic
activity of 18was detectable. Collectively these data demonstrate
that 18 is not susceptible to several important chemotherapy
resistance mechanisms.
Finally, the eﬀect of 18 was tested after 24 and 48 h of
treatment on the viability of peripheral blood mononuclear cells
(PBMCs) from healthy donors (Figure 13). Compound 18 does
not exhibit any major acute toxicity on this normal cell model.
■ CONCLUSIONS
We prepared new series of N-aryl-N′-3,4-dihydro-2,2-dimethyl-
2H-1-benzopyran-4-yl)ureas and thioureas bearing an alkoxycar-
bonylamino group (“carbamate” group) at the 6-position of the
Figure 4. Compound 18 docked into human SIRT1 and SIRT2. (A) Docking pose of compound 18 on the crystal structure of SIRT1 (light pink;
PDB code 4I5I). Close-up view on the right shows that compound 18 (lime) binds to the active site of SIRT1 structure. Hydrogen bonds are shown as
dashed black lines. The residues forming hydrophobic interactions are represented as gray colored sticks. (B) Docking pose of compound 18 on the
crystal structure of SIRT2 (wheat; PDB code 4RMG). Close-up view on the right shows that compound 18 (lime) binds to the active site of SIRT2
structure. The hydrogen bond is shown as dashed black lines. The residues forming hydrophobic interactions are represented as gray colored sticks.
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chroman nucleus. These compounds, structurally related to
previously described 2,2-dimethylchroman derivatives acting on
glioma cells, were examined as putative anticancer agents.
Growth inhibitory activity wasmeasured in three glioma cell lines
(U373, T98G, and Hs683), as well as on normal astrocytes.
Those data revealed that the compound bearing a cyano group at
the meta position of the phenyl ring of the 4-arylurea moiety, as
well as a bulky tert-butoxycarbonylamino group at the 6-position
(compound 18), exhibited a potent antiproliferative activity
against the tumor glial cells while having lower impact on normal
glial cells (selectivity index of >10). From the computational
docking analysis, compound 18 also showed a potent binding
aﬃnity when compared with other derivatives as observed with
our antiproliferative activity assay. This compound was therefore
selected for further investigations to better understand its
mechanism of action. Compound 18 was assayed in the NCI-60
cell line panel screening demonstrating interesting inhibitory
potential in various cell types. 18 was also submitted to a
COMPARE analysis (results not presented) to further decipher
the mode of action of compound 18 as successfully done pre-
viously with respect to other compounds but without providing
further clues. The screening conﬁrmed the antiproliferative
Table 4. Qualitative Molecular Docking of Compound 18
against Human SIRT1 (A) and SIRT2 (B)a
(A)
SIRT1 PDB code 18 2 3
4I5I −11.1 −7.0 −9.4
4IG9 −8.5 −8.8 −7.3
4ZZH −8.5 −8.4 −7.5
4ZZI −9.9 −9.9 −8.7
4ZZJ −7.4 −9.8 −8.8
5BTR −8.4 −7.9 −6.8
average −9.0 −8.6 −8.1
(B)
SIRT2 PDB code 18 2 4
4RMG −10.0 −8.7 −11.3
4RMH −10.6 −8.8 −11.5
1J8F −7.5 −9.8 −9.3
3ZGO −8.1 −10.3 −9.1
3ZGV −9.1 −9.8 −8.7
5DY4 −9.4 −11.0 −10.6
5DY5 −9.5 −7.5 −9.8
average −9.2 −9.4 −10.0
aBinding aﬃnity energy values (kcal/mol) for the indicated PDB
codes were calculated using AutoDock Vina program (for more details
see Experimental Section). 2, 3, and 4 were used as reference inhib-
itors of SIRT1/2, SIRT1, and SIRT2, respectively.
Table 5. Inhibitory Activity of Selected SIRT Inhibitors and
Compound 18 on SIRT1, -2, and -3 Activities
IC50 (μM)
a
compd SIRT1 SIRT2 SIRT3
1 2.8 ± 0.3 13 ± 1 >200
2 82.5 ± 7.1 47.1 ± 4.0 -
3 0.10 ± 0.06 20.1 ± 4.2 -
4 98.1 ± 2.4 2.8 ± 1.0 -
8 >200 >200 -
16 32.1 ± 6.5 18.5 ± 3.6 -
18 6.2 ± 1.7 4.2 ± 1.6 >200
19 >200 99.8 ± 11.0 -
25 121.2 ± 18.3 110.2 ± 18.9 -
35 109.9 ± 6.1 49.4 ± 7.6 -
36 108.7 ± 5.9 51.1 ± 11.1 -
37 54.8 ± 8.3 22.7 ± 3.5 -
aIC50 values: concentration of drug required for the inhibition of 50%
of the speciﬁed sirtuin activity [mean ± SD (n = 3 independent
experiments)]. 1 and 2, 3, and 4 were used as in vitro reference inhib-
itors of SIRT1/2, SIRT1, and SIRT2, respectively. “-”: not deter-
mined.
Figure 5. In vitro HDAC inhibition potential of compound 18.
(A) Residual inhibition of total HDAC activity. (B) Eﬀect of 18 on
activity of selected HDAC isoenzymes. Data are the mean± SD of three
independent experiments.
Figure 6. In cellulo assessment of HDAC inhibition by compound 18
through the study of histone and α-tubulin acetylation levels. Cells were
treated for 8 h at the indicated concentrations of compound 18. The
acetylation (Ac) of histone H4 (H4) and α-tubulin was analyzed by
Western blot. Histone H1 (H1) and β-actin were used as loading
controls for the analysis of acid (top panel) and total (bottom panel)
extracts, respectively. 38 (2 μM) was used as a reference HDAC
inhibitor.
Table 6. Growth Inhibitory Activities of Selected SIRT




2 39.3 ± 5.4 33.9 ± 4.3
3 157.4 ± 23.0 115.9 ± 23.3
4 47.6 ± 4.4 80.2 ± 9.3
18 7.5 ± 1.1 5.8 ± 0.9
aIC50 values: concentration of drug responsible for the inhibition of
50% of the growth of the speciﬁed cell line after 72 h [mean ± SEM of
three independent experiments (n = 4 replicates)].
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activity of 18 on a variety of cancer cell lines (mean GI50 value of
3 μM), while the COMPARE tool did not allow obtaining a clear
hypothesis about its potential mechanism of action. Quantitative
videomicroscopy analysis revealed that 18 was a cytostatic rather
than a cytotoxic agent.
Furthermore, neither mutation of p53 nor overexpression of
MDR eﬄux pumps including ABCB1 and ABCC1 signiﬁcantly
reduced the anticancer activity of 18. The same holds true for
acquired cisplatin and hydroxyurea resistance. These data
suggest that several major drug resistance mechanisms limiting
the success of current systemic cancer therapy are not aﬀecting
the activity of 18. Hence this substance might be especially
attractive for targeting treatment-resistant recurrences.
Then, 18 was tested against a panel of HDAC activities and
a potent inhibitory activity was observed in vitro on HDAC
SIRT1/2 and IC50 values in the low micromolar range (Table 3).
Presently, we cannot exclude that inhibition of other SIRT
isoforms led to growth arrest if expressed by the targeted cancer
type. This observation was validated in cellulo when 18 was
investigated on human U373 and Hs683 glioblastoma cell lines
to assess eﬀects of deacetylase inhibition on acetylation levels of
histone and non-histone proteins. Interestingly, compound 18
acted as an in vitro SIRTi with activities commonly reported in
the literature. Importantly we demonstrated associated biological
activities (i.e., increased protein acetylation levels and important
antiproliferative properties) at concentrations in the low micro-
molar range, which is usually not the case of SIRTi published
over the past years (Table SI-4).
Finally, the anticancer potential of 18 was further highlighted
through the growth inhibition of multicellular glioblastoma
tumor spheroids as well as the reduction of tumor formation in
vivo using zebraﬁsh xenografts.
In conclusion, compound 18 is new anticancer agent active on
glioma cells and expressing a cytostatic rather than a cytotoxic
activity. Moreover, this compound is a potent inhibitor of SIRT1
and -2 and constitutes a model of chemical structure opening
new perspectives in the medicinal chemistry of HDAC inhibitors
against class III.
■ EXPERIMENTAL SECTION
Chemistry. Melting points were determined on a Stuart SMP3
capillary apparatus and are uncorrected. The 1H NMR spectra were
recorded on a Bruker Avance (500MHz) instrument using DMSO-d6 as
the solvent with TMS as an internal standard; chemical shifts are
reported in δ values (ppm) relative to that of internal TMS. The
abbreviations s = singlet, d = doublet, t = triplet, q = quadruplet,
m = multiplet, b = broad are used throughout. Elemental analyses
(C, H, N, S) were realized on a Thermo Scientiﬁc FlashEA 1112
elemental analyzer and were within±0.4% of the theoretical values. This
analytical method certiﬁed a purity of ≥95% for each tested com-




ophenyl isocyanate (0.13 g, 0.82 mmol) was added to a solution of 9
(0.2 g, 0.68 mmol) in methylene chloride (5 mL). After 1 h, the solvent
was removed under vacuum; the title product was obtained from the
crude product by DCVC puriﬁcation: mp 192−194 °C; 1H NMR
(DMSO-d6) δ 1.25 (s, 3H, CH3), 1.36 (s, 3H, CH3), 1.43 (s, 9H,
NHCOOC(CH3)3), 1.66 (dd, J = 13 Hz/11 Hz, 1H, 3-H), 2.13 (dd, J =
13 Hz/6 Hz, 3-H), 4.91 (dd, J = 16 Hz/9 Hz, 1H, 4-H), 6,65 (d,
J = 8.8 Hz, 1H, 8-H), 6.97 (td, J = 7.9 Hz/1.5 Hz, 1H, 4′-H), 7.19 (d, J =
7.1 Hz, 1H, 7-H), 7.27 (td, J = 7.9 Hz/1.5 Hz, 1H, 5′-H), 7.38 (d, J =
8.4 Hz, 1H, CHNHCONHAr), 7.41−7.42 (m, 2H, 5-H/3′-H), 8.07 (s,
1H, CHNHCONHAr), 8.26 (dd, J = 8.3 Hz/1.2 Hz, 1H, 6′-H), 9.10 (s,
1H, NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.6 (CH3), 28.1
(C(CH3)3), 28.9 (CH3), 40.0 (C-3), 42.4 (C-4), 74.7 (C-2), 78.6
(C(CH3)3), 116.7 (C-8), 117.7 (C-5), 119.7 (C-7), 120.7 (C-6′), 121.1
(C-2′), 122.5 (C-4′), 122.6 (C-4a), 127.5 (C-5′), 129.1 (C-3′), 132.1
(C-6), 136.6 (C-1′), 148.6 (C-8a), 153.0 (NHCOOC(CH3)3), 154.7
(CHNHCONHAr). Anal. (C23H28ClN3O4) theoretical: C, 61.95; H,
6.33; N, 9.42. Found: C, 61.71; H, 6.33; N, 9.44.
R/S-N-2-Cyanophenyl-N′-(6-tert-butoxycarbonylamino-3,4-
dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (11). The title
compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 2-cyanophenyl isocyanate (0.12 g, 0.82 mmol): mp
206−208 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H, CH3), 1.36 (s, 3H,
CH3), 1.43 (s, 9H, NHCOOC(CH3)3), 1.69 (dd, J = 13 Hz/11 Hz, 1H,
3-H), 2.14 (dd, J = 13 Hz/6 Hz, 3-H), 4.91 (dd, J = 16 Hz/9 Hz, 1H,
4-H), 6,65 (d, J = 8.8 Hz, 1H, 8-H), 7.12 (t, J = 8 Hz, 1H, 4′-H), 7.20 (d,
J = 7.3 Hz, 1H, 7-H), 7.42 (d, J = 8.8 Hz, 1H, CHNHCONHAr), 7.43 (s,
1H, 5-H), 7.61 (m, 1H, 5′-H), 7.71 (dd, J = 7.8 Hz/1.4 Hz, 3′-H), 8.22
(d, J = 8.5 Hz, 1H, 6′-H), 8.54 (s, 1H, CHNHCONHAr), 9.11 (s, 1H,
NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.6 (CH3), 28.1
(C(CH3)3), 28.8 (CH3), 40.0 (C-3), 42.6 (C-4), 74.7 (C-2), 78.6
(C(CH3)3), 100.5 (C-2′), 116.8 (C-8), 117.0 (CN), 117.6 (C-5), 119.7
(C-7), 120.4 (C-6′), 122.2 (C-4′), 122.4 (C-4a), 132.1 (C-6), 133.0
(C-3′), 133.9 (C-5′), 142.7 (C-1′), 148.5 (C-8a), 153.0 (NHCOOC-
(CH3)3), 154.4 (CHNHCONHAr). Anal. (C24H28N4O4) theoretical:
C, 66.04; H, 6.47; N, 12.84. Found: C, 66.12; H, 6.11; N, 13.26.
R/S-N-2-Nitrophenyl-N′-(6-tert-butoxycarbonylamino-3,4-di-
hydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (12). The title
compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 2-nitrophenyl isocyanate (0.13 g, 0.82 mmol): mp
218−219 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H, CH3), 1.37 (s, 3H,
CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.69 (dd, J = 13 Hz/11 Hz, 1H,
3-H), 2.11 (dd, J = 13 Hz/6 Hz, 3-H), 4.92 (dd, J = 16 Hz/9 Hz, 1H,
Figure 7. SIRT1 or SIRT2 knock-down enhances the growth inhibitory eﬀects of 18 in glioblastoma cells. U373 and Hs683 cell lines were transfected
with the indicated siRNA. 24 h post-transfection cells were treated with compound 18 at the respective IC50 values calculated from MTT assays
(Table 6), and proliferation wasmonitored by time-lapse videomicroscopy. Graphs are representative of three independent experiments and correspond
to the mean ± SD of 16 pictures per well acquired in triplicate.
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4-H), 6,65 (d, J = 8.8 Hz, 1H, 8-H), 7.16 (m, 1H, 4′-H), 7.20 (d, J =
6.4 Hz, 1H, 7-H), 7.40 (s, 1H, 5-H), 7.68 (m, 1H, 5′-H), 7.98 (d, J =
8.1 Hz, 1H, CHNHCONHAr), 8.09 (dd, J = 8.4 Hz/1.5 Hz, 1H, 6′-H),
8.45 (d, J = 8.5 Hz, 1H, 3′-H), 9.09 (s, 1H, NHCOOC(CH3)3), 9.45 (s,
1H, CHNHCONHAr). 13C NMR (DMSO-d6) δ 24.4 (CH3), 28.1
(C(CH3)3), 29.0 (CH3), 40.0 (C-3), 42.7 (C-4), 74.7 (C-2), 78.6
(C(CH3)3), 116.7 (C-8), 117.7 (C-5), 119.6 (C-7), 121.5 (C-4′), 122.1
(C-3′), 122.4 (C-4a), 125.4 (C-6′), 132.0 (C-6), 135.0 (C-5′), 135.8
(C-1′), 136.7 (C-2′), 148.5 (C-8a), 152.9 (NHCOOC(CH3)3), 154.2
(CHNHCONHAr). Anal. (C23H28N4O6) theoretical: C, 60.52; H, 6.18;
N, 12.27. Found: C, 60.18; H, 6.17; N, 11.86.
R/S-N-2-Triﬂuoromethylphenyl-N′-(6-tert-butoxycarbonyl-
amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea
(13).The title compoundwas obtained as described for 10, starting from
9 (0.2 g, 0.68 mmol) and 2-triﬂuoromethylphenyl isocyanate (0.15 g,
0.82 mmol): mp 239−239.5 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H,
CH3), 1.36 (s, 3H, CH3), 1.44 (s, 9H, NHCOOC(CH3)3), 1.67
(dd, J = 13 Hz/11 Hz, 1H, 3-H), 2.12 (dd, J = 13 Hz/6 Hz, 3-H), 4.90
Figure 8. Digitized images of Hs683 oligodendroglial (A) and U373 glioblastoma (B) cells were obtained using computer-assisted phase-contrast
microscopy (quantitative videomicroscopy). A global growth ratio (the GGR index) was calculated, resulting in a value that can be directly compared to
the IC50 value determined by the MTT colorimetric assay (the hatched horizontal line in the bottom chart, i.e.,∼10 μM (see Table 1)). First, the global
growth (GG) is calculated for each control and each treated condition at 24, 48, and 72 h by dividing the number of cells on the last image by the number
of cells on the ﬁrst image. The GGR index is obtained by dividing the GG values calculated for Hs683 tumor cells treated with 18 by the GG values
calculated for the control. The experiment was performed once in triplicate, and the data represent the mean± SEM values. White, gray, and black bars
represent the data obtained at 24, 48 and 72 h, respectively.
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(dd, J = 16 Hz/9 Hz, 1H, 4-H), 6.64 (d, J = 8.8 Hz, 8-H), 7.15 (d, J = 7.6
Hz, 1H, 7-H), 7.21 (t, J = 7.6 Hz, 1H, 4′-H), 7.38 (d, J = 8.3 Hz, 1H,
CHNHCONHAr), 7.48 (s, 1H, 5-H), 7.60 (t, J = 7.8 Hz, 1H, 5′-H), 7.63
(d, J = 7.9 Hz, 1H, 3′-H), 7.83 (s, 1H, CHNHCONHAr), 8.09 (d, J =
8.3Hz, 1H, 6′-H), 9.12 (s, 1H,NHCOOC(CH3)3). 13CNMR(DMSO-d6)
δ 24.6 (CH3), 28.1 (C(CH3)3), 28.9 (CH3), 40.0 (C-3), 42.6 (C-4), 74.7
(C-2), 78.6 (C(CH3)3), 116.7 (C-8), 117.8 (C-5), 119.6 (C-7), 122.7
(C-4a), 122.8 (C-4′), 123.0−125.1 (d, J = 273 Hz, CF3), 124.8 (C-6′),
125.7 (C-3′), 127.3 (C-2′), 132.0 (C-6), 132.7 (C-5′), 137.2 (C-1′),
148.5 (C-8a), 152.9 (NHCOOC(CH3)3), 154.9 (CHNHCONHAr).
Anal. (C24H28F3N3O4) theoretical: C, 60.12; H, 5.89; N, 8.76. Found: C,
60.12; H, 5.95; N, 8.73.
R/S-N-2-Methoxyphenyl-N′-(6-tert-butoxycarbonylamino-
3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (14).
The title compound was obtained as described for 10, starting from 9
(0.2 g, 0.68 mmol) and 2-methoxyphenyl isocyanate (0.12 g, 0.82mmol):
mp 204−205 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H, CH3), 1.35 (s,
3H, CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.62 (dd, J = 13 Hz/11 Hz,
1H, 3-H), 2.10 (dd, J = 13Hz/6Hz, 3-H), 3.83 (s, 3H, OCH3), 4.90 (dd,
J = 16 Hz/9 Hz, 1H, 4-H), 6,63 (d, J = 8.8 Hz, 1H, 8-H), 6.88 (pd, J =
7.4 Hz/1.6 Hz, 2H, 4′-H/5′-H), 6.98 (dd, J = 7.7 Hz/1.6 Hz, 1H, 3′-H),
7.19 (bs, 1H, CHNHCONHAr), 7.20 (d, J = 8.5 Hz, 1H, 7-H), 7.40 (s,
1H, 5-H), 8.01 (s, 1H, CHNHCONHAr), 8.18 (dd, J = 7.5 Hz/1.9 Hz,
1H, 6′-H), 9.10 (s, 1H, NHCOOC(CH3)3). 13C NMR (DMSO-d6) δ
24.6 (CH3), 28.1 (C(CH3)3), 28.9 (CH3), 40.0 (C-3), 42.2 (C-4), 55.6
(OCH3), 74.7 (C-2), 78.5 (C(CH3)3), 110.5 (C-3′), 116.6 (C-8), 117.8
(C-5/C-6′), 119.6 (C-7), 120.5 (C-5′), 121.0 (C-4′), 122.9 (C-4a), 129.4
(C-1′), 132.0 (C-6), 147.2 (C-2′), 148.6 (C-8a), 153.0 (NHCOOC-
(CH3)3), 155.0 (CHNHCONHAr). Anal. (C24H31N3O5) theoretical: C,
65.29; H, 7.08; N, 9.52. Found: C, 65.20; H, 7.09; N, 9.51.
Figure 9. Compound 18 induces G1 cell cycle arrest in glioblastoma cell lines and promotes the accumulation of senescent U373 cells. (A) Cells were
treated, or not, with 18, 2, 3, 4 (at the respective IC50 values for each cell lines reported in Table 6) and 2 μM 38. After 24 and 48 h of exposure, cell cycle
distribution was analyzed. Histograms correspond to the mean ± SD of the quantiﬁcation of three independent experiments. ∗, ∗∗ indicate p < 0.05,
p < 0.01 compared to control cells, respectively. (B) Cells were incubated in a medium containing DMSO as a vehicle control or 5 μM 18 for 6 days and
were stained for β-galactosidase activity. Representative pictures of two independent experiments are depicted where SA-β-gal-positive cells are revealed
by blue staining. The percentage of senescent cells, expressed as a percentage of the total number of cells counted, is indicated for each picture. Data
represent the mean ± SD of two independent experiments.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00533
J. Med. Chem. 2017, 60, 4714−4733
4725
R/S-N-3-Fluorophenyl-N′-(6-tert-butoxycarbonylamino-3,4-
dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (15). The title
compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 3-ﬂuorophenyl isocyanate (0.11 g, 0.82 mmol): mp
115−125 °C; 1H NMR (DMSO-d6) δ 1.24 (s, 3H, CH3), 1.35 (s, 3H,
CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.70 (dd, J = 13 Hz/11 Hz, 1H,
3-H), 2.08 (dd, J = 13 Hz/6 Hz, 3-H), 4.92 (dd, J = 16 Hz/10 Hz, 1H,
4-H), 6.55 (d, J = 8.6 Hz, 1H, CHNHCONHAr), 6,64 (d, J = 8.7 Hz, 1H,
8-H), 6.73 (t, J = 7.6 Hz, 1H, 4′-H), 7.06 (d, J = 7.8 Hz, 1H, 6′-H), 7.17
(d, J = 7.1Hz, 1H, 7-H), 7.26 (dd, J = 15.2Hz/7.7 Hz, 1H, 5′-H), 7.41 (s,
1H, 5-H), 7.53 (d, J = 12 Hz, 1H, 2′-H), 8.73 (s, 1H, CHNHCONHAr),
9.11 (s, 1H, NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.4 (CH3),
28.1 (C(CH3)3), 29.0 (CH3), 40.0 (C-3), 42.3 (C-4), 74.8 (C-2), 78.5
(C(CH3)3), 104.4 (d, J = 27 Hz, C-2′), 107.4 (d, J = 21 Hz, C-4′), 113.5
(d, J = 2Hz, C-6′), 116.7 (C-8), 117.6 (C-5), 119.6 (C-7), 122.9 (C-4a),
130.1 (d, J = 10 Hz, C-5′), 132.0 (C-6), 142.2 (d, J = 12 Hz, C-1′), 148.5
(C-8a), 152.9 (NHCOOC(CH3)3), 154.9 (CHNHCONHAr), 161.5−
163.4 (d, J = 240 Hz, C-3′). Anal. (C23H28FN3O4) theoretical: C, 64.32;
H, 6.57; N, 9.78. Found: C, 64.68; H, 6.26; N, 10.09.
R/S-N-3-Bromophenyl-N′-(6-tert-butoxycarbonylamino-3,4-
dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (17). The
title compound was obtained as described for 10, starting from 9
(0.2 g, 0.68 mmol) and 3-bromophenyl isocyanate (0.16 g, 0.82 mmol):
mp 209.5−210.5 °C; 1HNMR (DMSO-d6) δ 1.24 (s, 3H, CH3), 1.35 (s,
3H, CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.71 (dd, J = 13 Hz/11 Hz,
1H, 3-H), 2.08 (dd, J = 13 Hz/6 Hz, 3-H), 4.92 (dd, J = 16 Hz/10 Hz,
1H, 4-H), 6.57 (d, J = 8.6Hz, 1H, CHNHCONHAr), 6,63 (d, J = 8.7Hz,
1H, 8-H), 7.09 (d, J = 8.5 Hz, 1H, 4′-H), 7.16 (d, J = 7.1 Hz, 1H, 7-H),
7.20 (t, J = 8 Hz, 1H, 5′-H), 7.26 (d, J = 8.7 Hz, 1H, 6′-H), 7.40 (s, 1H,
5-H), 7.90 (t, J = 1.9 Hz, 1H, 2′-H), 8.71 (s, 1H, CHNHCONHAr), 9.09
(s, 1H, NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.4 (CH3), 28.1
(C(CH3)3), 29.0 (CH3), 40.0 (C-3), 42.4 (C-4), 74.8 (C-2), 78.5
(C(CH3)3), 116.6 (C-8/C-6′), 117.5 (C-5), 119.6 (C-7), 120.1 (C-2′),
121.7 (C-3′), 122.9 (C-4a), 123.7 (C-4′), 130.6 (C-5′), 132.0 (C-6),
142.0 (C-1′), 148.5 (C-8a), 152.9 (NHCOOC(CH3)3), 154.9
(CHNHCONHAr). Anal. (C23H28BrN3O4) theoretical: C, 56.33; H,
5.76; N, 8.57. Found: C, 56.40; H, 5.83; N, 8.44.
R/S-N-3-Nitrophenyl-N′-(6-tert-butoxycarbonylamino-3,4-di-
hydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (19). The title
compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 3-nitrophenyl isocyanate (0.13 g, 0.82 mmol): mp
120−155 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H, CH3), 1.36 (s, 3H,
CH3), 1.41 (s, 9H, NHCOOC(CH3)3), 1.76 (dd, J = 13 Hz/11 Hz, 1H,
3-H), 2.09 (dd, J = 13 Hz/6 Hz, 3-H), 4.95 (dd, J = 16 Hz/10 Hz, 1H,
4-H), 6.64 (d, J = 8.8 Hz, 1H, 8-H), 6.71 (d, J = 8.7 Hz, 1H,
CHNHCONHAr), 7.17 (bs, 1H, 7-H), 7.41 (s, 1H, 5-H), 7.53 (t, J =
8.2 Hz, 1H, 5′-H), 7.69 (d, J = 7.8 Hz, 1H, 4′-H), 7.78 (d, J = 8.1 Hz, 1H,
6′-H), 8.61 (t, J = 2 Hz, 1H, 2′-H), 9.09 (s, 2H, CHNHCONHAr/
NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.4 (CH3), 28.1
(C(CH3)3), 29.1 (CH3), 40.0 (C-3), 42.5 (C-4), 74.8 (C-2), 78.5
(C(CH3)3), 111.7 (C-2′), 115.7 (C-6′), 116.7 (C-8), 117.5 (C-5), 119.6
(C-7), 122.8 (C-4a), 123.9 (C-4′), 129.9 (C-5′), 132.0 (C-6), 141.7
(C-1′), 148.1 (C-3′), 148.5 (C-8a), 152.9 (NHCOOC(CH3)3), 154.9
(CHNHCONHAr). Anal. (C23H28N4O6) theoretical: C, 60.52; H, 6.18;
N, 12.27. Found: C, 61.01; H, 6.13; N, 12.18.
R/S-N-3-Triﬂuoromethylphenyl-N′-(6-tert-butoxycarbonyl-
amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea
(20).The title compoundwas obtained as described for 10, starting from
9 (0.2 g, 0.68 mmol) and 3-triﬂuoromethylphenyl isocyanate (0.15 g,
0.82 mmol): mp 140−155 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H,
CH3), 1.36 (s, 3H, CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.74 (dd,
J = 13 Hz/11 Hz, 1H, 3-H), 2.09 (dd, J = 13 Hz/6 Hz, 3-H), 4.94 (dd,
Figure 10. continued
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J = 16 Hz/10 Hz, 1H, 4-H), 6.62 (d, J = 8.6 Hz, 1H, CHNHCONHAr),
6.64 (d, J = 8.8 Hz, 1H, 8-H), 7.17 (bd, J = 6.7 Hz, 1H, 7-H), 7.26 (d, J =
7.5 Hz, 1H, 4′-H), 7.41 (s, 1H, 5-H), 7.47 (t, J = 7.9 Hz, 1H, 5′-H),
7.53 (d, J = 8.2 Hz, 1H, 6′-H), 8.07 (s, 1H, 2′-H), 8.89 (s, 1H,
CHNHCONHAr), 9.08 (s, 1H, NHCOOC(CH3)3).
13C NMR
(DMSO-d6) δ 24.4 (CH3), 28.1 (C(CH3)3), 29.1 (CH3), 40.0 (C-3),
42.4 (C-4), 74.8 (C-2), 78.5 (C(CH3)3), 113.8 (C-2′), 116.6 (C-8),
117.4 (C-5/C-4′), 119.6 (C-7), 121.3 (C-6′), 122.9 (C-4a), 123.2−
125.4 (d, J = 272 Hz, CF3), 129.3−129.6 (d, J = 31 Hz, C-3′), 129.7
(C-5′), 132.0 (C-6), 141.2 (C-1′), 148.5 (C-8a), 153.0 (NHCOOC-
(CH3)3), 155.0 (CHNHCONHAr). Anal. (C24H28F3N3O4) theoretical:
C, 60.12; H, 5.89; N, 8.76. Found: C, 60.19; H, 6.03; N, 8.59.
R/S-N-3-Methoxyphenyl-N′-(6-tert-butoxycarbonylamino-
3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (21). The
title compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 3-methoxyphenyl isocyanate (0.12 g, 0.82 mmol): mp
189−191 °C; 1H NMR (DMSO-d6) δ 1.24 (s, 3H, CH3), 1.35 (s, 3H,
CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.68 (dd, J = 13 Hz/11 Hz, 1H,
3-H), 2.08 (dd, J = 13 Hz/6 Hz, 3-H), 3.72 (s, 1H, OCH3), 4.91 (dd, J =
16Hz/10Hz, 1H, 4-H), 6.46 (d, J = 8.7Hz, 1H, CHNHCONHAr), 6.50
(dd, J = 8.2 Hz/1.9 Hz, 1H, 4′-H), 6.63 (d, J = 8.8 Hz, 1H, 8-H), 6.89
(dd, J = 8.1 Hz/1 Hz, 1H, 6′-H), 7.13 (t, J = 8 Hz, 1H, 5′-H), 7.17 (d, J =
7.8 Hz, 1H, 7-H), 7.22 (t, J = 2 Hz, 1H, 2′-H), 7.40 (s, 1H, 5-H), 8.52 (s,
1H, CHNHCONHAr), 9.08 (s, 1H, NHCOOC(CH3)3).
13C NMR
(DMSO-d6) δ 24.5 (CH3), 28.1 (C(CH3)3), 29.0 (CH3), 40.0 (C-3),
42.3 (C-4), 54.8 (OCH3), 74.8 (C-2), 78.5 (C(CH3)3), 103.4 (C-2′),
106.7 (C-4′), 110.1 (C-6′), 116.6 (C-8), 117.6 (C-5), 119.6 (C-7),
123.0 (C-4a), 129.4 (C-5′), 132.0 (C-6), 141.6 (C-1′), 148.6 (C-8a),
153.0 (NHCOOC(CH3)3), 155.0 (CHNHCONHAr), 159.7 (C-3′).
Figure 10. Antitumor potential of compound 18. (A) Representative bright ﬁeld images and 3D plots of spheroids generated from Hs683 cells (top
panels). Cells were pretreated for 24 h with the indicated concentrations of 18 and then left untreated for 96 h (4-day incubation, upper left panel), or
untreated cells were cultured for 96 h in the presence of the indicated concentrations of 18 (24 h pretreated cells, upper right panel). The surface,
volume, and ATP levels of spheroids were measured as described in the Experimental Section (bottom panels). Data are the mean ± SD of three
independent experiments. (B) Fluorescent Hs683 and U373 cells were treated, or not, in vitro at 5 or 10 μM compound 18 for 30 or 36 h and then
injected in the zebraﬁsh yolk sac. The ﬁgure represents results obtained with a pretreatment of 36 h at 10 μM; for the other conditions of treatment we
refer to Figure SI-5. After 72 h, ﬂuorescence was quantiﬁed and representative images from a total of eight ﬁsh per condition are shown. For each ﬁsh, the
upper panel represents the bright ﬁeld, the middle panel the red ﬂuorescence, and the bottom panel the merged picture. Fluorescence intensity
quantiﬁcation graphs are shown. PBS injection was used as a control for injection side eﬀects. ∗, ∗∗, ∗∗∗ indicate p < 0.05, p < 0.01, p < 0.05 compared to
control cells, respectively.
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Anal. (C24H31N3O5) theoretical: C, 65.29; H, 7.08; N, 9.52. Found: C,
65.25; H, 7.13; N, 9.43.
R/S-N-3-Aminomethylphenyl-N′-(6-tert-butoxycarbonyl-
amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea
(22). Raney nickel was added to a solution of 18 (0.3 g, 0.69 mmol)
and ammonia (0.3 mL) in ethanol (10 mL). The solution was stirred
in a sealed hydrogenator under a hydrogen pressure of 7 bar. When
the reaction was ended (3 h), the catalyst was ﬁltered oﬀ and the
ﬁltrate was evaporated under pressure. The title compound was
obtained after puriﬁcation on a DCVC system: mp 120−170 °C; 1H
NMR (DMSO-d6) δ 1.24 (s, 3H, CH3), 1.35 (s, 3H, CH3), 1.42 (s, 9H,
NHCOOC(CH3)3), 1.68 (dd, J = 13 Hz/11 Hz, 1H, 3-H), 2.09 (dd, J =
13 Hz/6 Hz, 3-H), 3.3 (bs, 2H, CH2NH2), 3.67 (s, 2H, CH2NH2),
4.91 (dd, J = 16 Hz/10 Hz, 1H, 4-H), 6.47 (d, J = 8.7 Hz, 1H,
CHNHCONHAr), 6.63 (d, J = 8.8Hz, 1H, 8-H), 6.89 (d, J = 7.5 Hz, 1H,
4′-H), 7.17 (m, 2H, 7-H/5′-H), 7.31 (d, J = 8.2 Hz, 1H, 6′-H), 7.37 (s,
1H, 2′-H), 7.41 (s, 1H, 5-H), 8.46 (s, 1H, CHNHCONHAr), 9.08 (s,
1H, NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.5 (CH3), 28.1
(C(CH3)3), 29.0 (CH3), 40.0 (C-3), 42.3 (C-4), 45.7 (CH2NH2), 74.8
(C-2), 78.5 (C(CH3)3), 115.8 (C-6′), 116.5 (C-2′), 116.7 (C-8),
117.5 (C-5), 119.6 (C-7), 120.0 (C-4′), 123.0 (C-4a), 128.4 (C-5′),
132.0 (C-6), 140.2 (C-1′), 144.5 (C-3′), 148.6 (C-8a), 153.0
(NHCOOC(CH3)3), 155.1 (CHNHCONHAr). Anal. (C24H32N4O4)




nium chloride (0.15 g, 2.83 mmol) and iron (0.6 g, 10,7 mmol) were
added to a solution of 19 (0.3 g, 0.66 mmol) in ethanol/water 3:1
(10 mL). The solution was heated at 80 °C for 15 min. After ﬁltration
(without cooling), the ﬁltrate was treated with charcoal, ﬁltered, and
evaporated under vacuum. The title compound was obtained after puri-
ﬁcation on a DCVC system: mp 130−140 °C; 1H NMR (DMSO-d6) δ
1.24 (s, 3H, CH3), 1.35 (s, 3H, CH3), 1.43 (s, 9H, NHCOOC(CH3)3),
1.65 (dd, J = 13 Hz/11 Hz, 1H, 3-H), 2.08 (dd, J = 13 Hz/6 Hz, 3-H),
4.89 (dd, J = 16 Hz/10 Hz, 1H, 4-H), 4.95 (s, 1H, NH2), 6.14 (dd, J =
7.9 Hz/1.3 Hz, 1H, 4′-H), 6.35 (d, J = 8.7 Hz, 1H, CHNHCONHAr),
6.57 (dd, J = 8.1 Hz/1 Hz, 1H, 6′-H), 6.63 (d, J = 8.8 Hz, 1H, 8-H), 6.72
(t, J = 1.9 Hz, 1H, 2′-H), 6.85 (t, J = 8 Hz, 1H, 5′-H), 7.17 (d, J = 6.6 Hz,
1H, 7-H), 7.39 (s, 1H, 5-H), 8.17 (s, 1H, CHNHCONHAr), 9.10 (s, 1H,
NHCOOC(CH3)3).
13C NMR (DMSO-d6) δ 24.6 (CH3), 28.1
(C(CH3)3), 29.0 (CH3), 40.0 (C-3), 42.2 (C-4), 74.8 (C-2), 78.5
(C(CH3)3), 103.4 (C-2′), 105.8 (C-6′), 107.6 (C-4′), 116.6 (C-8),
117.7 (C-5), 119.6 (C-7), 123.1 (C-4a), 128.9 (C-5′), 132.0 (C-6),
140.9 (C-1′), 148.6 (C-8a), 149.0 (C-3′), 153.0 (NHCOOC(CH3)3),
154.9 (CHNHCONHAr). Anal. (C23H30N4O4) theoretical: C, 64.77;
H, 7.09; N, 13.14. Found: C, 64.32; H, 7.06; N, 12.95.
R/S-N-4-Nitrophenyl-N′-(6-tert-butoxycarbonylamino-3,4-di-
hydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (26). The title
compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 4-nitrophenyl isocyanate (0.13 g, 0.82 mmol): mp
233−233.5 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H, CH3), 1.36 (s, 3H,
CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.75 (dd, J = 13 Hz/11 Hz,
1H, 3-H), 2.10 (dd, J = 13 Hz/6 Hz, 3-H), 4.94 (dd, J = 16 Hz/9 Hz, 1H,
4-H), 6.64 (d, J = 8.8 Hz, 1H, 8-H), 6.82 (d, J = 8.6 Hz, 1H,
CHNHCONHAr), 7.18 (d, J = 6.5 Hz, 1H, 7-H), 7.40 (s, 1H, 5-H), 7.69
(d, J = 7.7 Hz, 2H, 2′-H/6′-H), 8.17 (d, J = 9.3 Hz, 2H, 3′-H/5′-H), 9.09
(s, 1H, NHCOOC(CH3)3), 9.32 (s, 1H, CHNHCONHAr).
13C NMR
(DMSO-d6) δ 24.4 (CH3), 28.1 (C(CH3)3), 29.0 (CH3), 40.4 (C-3),
42.5 (C-4), 74.8 (C-2), 78.6 (C(CH3)3), 116.7 (C-8), 117.0 (C-2′/C-6′),
117.5 (C-5), 119.6 (C-7), 122.5 (C-4a), 125.1 (C-3′/C-5′), 132.1 (C-6),
140.5 (C-1′), 147.0 (C-4′), 148.5 (C-8a), 152.9 (NHCOOC(CH3)3),
154.4 (CHNHCONHAr). Anal. (C23H28N4O6) theoretical: C, 60.52;
H, 6.18; N, 12.27. Found: C, 59.95; H, 6.16; N, 12.09.
R/S-N-4-Triﬂuoromethylphenyl-N′-(6-tert-butoxycarbonyl-
amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea
(27).The title compoundwas obtained as described for 10, starting from
9 (0.2 g, 0.68 mmol) and 4-triﬂuoromethylphenyl isocyanate (0.15 g,
0.82 mmol): mp 186−188 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H,
CH3), 1.36 (s, 3H, CH3), 1.42 (s, 9H, NHCOOC(CH3)3), 1.72 (dd, J =
13 Hz/11 Hz, 1H, 3-H), 2.09 (dd, J = 13 Hz/6 Hz, 3-H), 4.94 (dd, J =
16 Hz/9 Hz, 1H, 4-H), 6.63−6.66 (m, 2H, CHNHCONHAr/8-H),
7.18 (d, J = 7 Hz, 1H, 7-H), 7.40 (s, 1H, 5-H), 7.59 (d, J = 8.8 Hz, 2H,
3′-H/5′-H), 7.65 (d, J = 8.8 Hz, 1H, 2′-H/6′-H), 8.95 (s, 1H,
CHNHCONHAr), 9.09 (s, 1H, NHCOOC(CH3)3).
13C NMR
(DMSO-d6) δ 24.4 (CH3), 28.1 (C(CH3)3), 29.0 (CH3), 40.4 (C-3),
42.4 (C-4), 74.8 (C-2), 78.5 (C(CH3)3), 116.7 (C-8), 117.4 (C-5/C-2′/
C-6′), 119.6 (C-7), 121.0−121.2 (d, J = 32 Hz, C-4′), 122.8
(C-4a), 123.5−125.7 (d, J = 271 Hz, CF3), 126.0 (C-3′/C-5′), 132.0
(C-6), 144.1 (C-1′), 148.6 (C-8a), 153.0 (NHCOOC(CH3)3), 154.8
(CHNHCONHAr). Anal. (C24H28F3N3O4) theoretical: C, 60.12; H,
5.89; N, 8.76. Found: C, 60.08; H, 5.97; N, 8.72.
R/S-N-4-Methoxyphenyl-N′-(6-tert-butoxycarbonylamino-
3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea (28). The
title compound was obtained as described for 10, starting from 9 (0.2 g,
0.68 mmol) and 4-methoxyphenyl isocyanate (0.12 g, 0.82 mmol): mp
204−205 °C; 1H NMR (DMSO-d6) δ 1.24 (s, 3H, CH3), 1.35 (s, 3H,
CH3), 1.43 (s, 9H, NHCOOC(CH3)3), 1.68 (dd, J = 13 Hz/11 Hz, 1H,
3-H), 2.06 (dd, J = 13 Hz/6 Hz, 3-H), 3.70 (s, 3H, OCH3), 4.91 (dd, J =
16 Hz/9 Hz, 1H, 4-H), 6.47 (d, J = 8.7 Hz, 1H, CHNHCONHAr), 6,62
(d, J = 8.8 Hz, 1H, 8-H), 6.83 (d, J = 9 Hz, 2H, 3′-H/5′-H), 7.16 (d, J =
7.2 Hz, 7-H), 7.35 (d, J = 9 Hz, 2H, 2′-H/6′-H), 7.40 (s, 1H, 5-H), 8.41
Figure 11. Characterization of the growth inhibitory eﬀects exerted by
compound 18 in the NCI 60-cell-line panel (National Cancer Institute
Developmental Therapeutics Program, mean graphs).
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(s, 1H, CHNHCONHAr), 9.08 (s, 1H, NHCOOC(CH3)3).
13C NMR
(DMSO-d6) δ 24.4 (CH3), 28.1 (C(CH3)3), 29.1 (CH3), 40.0 (C-3),
42.3 (C-4), 55.1 (OCH3), 74.8 (C-2), 78.5 (C(CH3)3), 113.8 (C-3′/
C-5′), 116.6 (C-8), 117.7 (C-5), 119.5 (C-2′/C-6′), 119.6 (C-7), 123.3
(C-4a), 132.0 (C-6), 133.6 (C-1′), 148.6 (C-8a), 153.0 (NHCOOC-
(CH3)3), 154.0 (CHNHCONHAr), 155.4 (C-4′). Anal. (C24H31N3O5)
theoretical: C, 65.29; H, 7.08; N, 9.52. Found: C, 64.88; H, 7.20; N, 9.13.
R/S-N-3-Cyanophenyl-N′-(3,4-dihydro-2,2-dimethyl-2H-1-
benzopyran-4-yl)urea (32). The title compound was obtained as
described for 10, starting from 31 (0.2 g, 1.13mmol) and 3-cyanophenyl
isocyanate (0.18 g, 1.25 mmol): mp 217−219 °C; 1HNMR (DMSO-d6)
δ 1.28 (s, 3H, CH3), 1.39 (s, 3H, CH3), 1.77 (t, J = 12Hz, 1H, 3-H), 2.12
(dd, J = 13 Hz/6.2 Hz, 3-H), 4.98 (dd, J = 16.3 Hz/9.2 Hz, 1H, 4-H),
6.74 (d, J = 8.7 Hz, 1H, 8-H), 6.76 (d, J = 10 Hz, 1H, CHNHCONHAr),
6.88 (t, J = 7.4 Hz, 1H, 6-H), 7.14 (t, J = 7.6 Hz, 1H, 7-H), 7.26
(d, J = 7.6 Hz, 1H, 5-H), 7.37 (d, J = 7.5 Hz, 1H, 4′-H), 7.46 (t, J = 8 Hz,
1H, 5′-H), 7.64 (d, J = 8.3 Hz, 1H, 6′-H), 8.00 (s, 1H, 2′-H), 8.92 (s, 1H,
CHNHCONHAr). 13C NMR (DMSO-d6) δ 25.0 (CH3), 29.6 (CH3),
40.0 (C-3), 42.8 (C-4), 75.6 (C-2), 117.2 (C-8), 119.4 (CN), 120.4
(C-6), 120.8 (C-2′), 122.9 (C-6′), 123.7 (C-4a), 125.1 (C-4′), 128.0
(C-5), 129.0 (C-7), 130.6 (C-5′), 141.8 (C-1′), 153.8 (C-8a), 155.5
(CHNHCONHAr). Anal. (C19H19N3O2) theoretical: C, 71.01; H, 5.96;
N, 13.08. Found: C, 70.90; H, 5.97; N, 12.83.
R/S-N-3-Cyanophenyl-N′-(6-amino-3,4-dihydro-2,2-dimeth-
yl-2H-1-benzopyran-4-yl)urea (33). A suspension of 18 (2.85 g,
6.5 mmol) in a 5 N hydrochloric acid ethanolic solution (100 mL) was
heated for 5 min. The mixture was then poured into water (200 mL).
The title compound was precipitated by addition of a 20% aqueous
solution of sodium hydroxide until pH = 10, ﬁltered, washed with water,
and dried: mp 176−178 °C; 1H NMR (DMSO-d6) δ 1.21 (s, 3H, CH3),
1.32 (s, 3H, CH3), 1.67 (dd, J = 13 Hz/11 Hz, 1H, 3-H), 2.03 (dd, J = 13
Hz/6.3 Hz, 3-H), 4.57 (s, 2H, NH2), 4.87 (dd, J = 15.9 Hz/9.7 Hz,
1H, 4-H), 6.40 (dd, J = 8.5 Hz/2.5 Hz, 1H, 7-H), 6.45 (d, J = 8.5 Hz, 1H,
8-H), 6.51 (d, J = 2.2 Hz, 1H, 5-H), 6.63 (d, J = 8.7 Hz, 1H,
CHNHCONHAr), 7.36 (d, J = 7.7 Hz, 1H, 4′-H), 7.45 (t, J = 8 Hz, 1H,
5′-H), 7.63 (d, J = 8.3 Hz, 1H, 6′-H), 8.00 (s, 1H, 2′-H), 8.86 (s, 1H,
CHNHCONHAr). 13C NMR (DMSO-d6) δ 24.8 (CH3), 29.6 (CH3),
40.8 (C-3), 42.9 (C-4), 74.4 (C-2), 112.0 (C-3′), 112.7 (C-5), 115.7
(C-7), 117.4 (C-8), 119.5 (CN), 120.7 (C-2′), 122.8 (C-6′), 123.4
(C-4a), 125.1 (C-4′), 130.6 (C-5′), 141.8 (C-6), 142.2 (C-1′), 144.8
(C-8a), 155.4 (CHNHCONHAr). Anal. (C19H20N4O2) theoretical: C,
67.84; H, 5.99; N, 16.66. Found: C, 67.47; H, 6.03; N, 16.53.
R/S-N-3-Cyanophenyl-N′-(6-formamido-3,4-dihydro-2,2-di-
methyl-2H-1-benzopyran-4-yl)urea (34). A mixture of acetic
anhydride (2 mL, 21.2 mmol) and formic acid (1 mL, 26.5 mmol)
was heated at 55 °C for 2 h. The mixture was then cooled to 0 °C, and
anhydrous THF (2 mL) was added. A solution of 33 (0.3 g, 0.89 mmol)
in anhydrous THF was added dropwise. When the reaction was
complete, water was added and the resulting precipitate was ﬁltered,
washed with water, and dried. The title product was obtained from the
crude product by DCVC puriﬁcation: mp 200−202 °C; 1H NMR
(DMSO-d6) δ 1.26 (s, 3H, CH3), 1.37 (s, 3H, CH3), 1.76 (t, J = 12 Hz,
1H, 3-H), 2.09 (dd, J = 13 Hz/6.2 Hz, 3-H), 4.96 (dd, J = 15.3 Hz/
10.3 Hz, 1H, 4-H), 6.70 (d, J = 8.7 Hz, 1H, 8-H), 6.80 (d, J = 8.7 Hz, 1H,
CHNHCONHAr), 7.37 (d, J = 7.7 Hz, 1H, 4′-H), 7.42−7.48 (m, 3H,
5-H/7-H/5′-H), 7.66 (m, 1H, 6′-H), 8.01 (s, 1H, 2′-H), 8.15 (d, J =
2 Hz, 1H, NHCHO), 8.96 (s, 1H, CHNHCONHAr), 10.00 (s, 1H,
NHCHO). 13C NMR (DMSO-d6) δ 24.4 (CH3), 29.1 (CH3), 40.0
(C-3), 42.3 (C-4), 75.1 (C-2), 111.5 (C-3′), 116.8 (C-8), 118.3 (C-5),
119.0 (CN), 120.2 (C-7), 120.3 (C-2′), 122.4 (C-6′), 123.2 (C-4a),
124.0 (), 124.7 (C-4′), 130.1 (C-5′), 131.0 (C-6), 141.2 (C-1′), 149.5
Figure 12. Impact of clinically signiﬁcant drug resistance mechanisms on the anticancer activity of 18. (A) HCT-116 p53wt and HCT-116 p53ko (p53
knockout), (B) SW1573, SW1573 2R120 (ABCC1- and LRP-overexpressing) and 2R160 (ABCB1-overexpressing), (C) A2780 and A2780cis (cisplatin
resistant), and (D) KB-3-1, KB-C-1 (ABCB1-overexpressing) and KB-HU (ribonucleotide reductase subunit 2-overexpressing) were treated with the
indicated concentrations of compound 18. After 72 h of continuous drug exposure, cell viability was determined by MTT assay. The experiments were
performed in quintuplicate, and results are shown as the mean ± SD.
Figure 13. Eﬀect of compound 18 on the viability of healthy peripheral
blood mononuclear cells. Histograms correspond to the mean ± SD of
three independent experiments. ∗, ∗∗ indicate p < 0.05, p < 0.01
compared to control cells, respectively.
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(C-8a), 154.9 (CHNHCONHAr), 158.9 (NHCHO). Anal.
(C19H20N4OS) theoretical: C, 65.92; H, 5.53; N, 15.38. Found: C,
65.43; H, 5.55; N, 15.37.
Docking Studies. AutoDock Vina software (The Scripps Research
Institute, CA, USA)19 was used in the docking studies. Initial struc-
tures of SIRT1 and SIRT2 were obtained from the Protein Data Bank
(PDB), and coordinates for the compounds were generated using the
GlycoBioChem PRODRG2 server.36 To prepare the structure for
docking, the ligand and all water molecules were removed. The size of
the docking grid was 40 Å × 40 Å × 40 Å, which encompassed most of
the entire structures of SIRT1 and -2. AutoDock Vina program was run
with four-way multithreading, and the other parameters were default
settings in AutoDock Vina program. Figures were generated using
PyMol (DeLano, W. L. The PyMol Molecular Graphics System; DeLano
Scientiﬁc: Palo Alto, CA, USA, 2002) and LigPlot+.37
Pharmacology. Cell Cultures and Media. Three human glioma
cell lines were used (the Hs683 oligodendroglial and the U373 and
T98G glioblastoma models). The biological and histopathological
characteristics demonstrating the oligodendroglial nature of the Hs683
model were provided by Le Mercier et al.38 A controversy exists today
about the origin of the U373 cells, which are in fact U251 glioblastoma
cells.39 A new U373 cell line has been established and deposited at the
European Collection of Cell Cultures (Salisbury, U.K.; code ECACC
08061901). We used this U373 model in the current study. The T98G
glioma cell line was obtained from the American Type Culture
Collection (Manassas, VA, USA; code ATCC CRL-1690) and was
initially described by Stein.40 The Hs683 model was also obtained from
the ATCC (code HTB-138). The uterine cervix carcinoma-derived cell
line KB-3-1 and its ABCB1-overexpressing MDR subline KB-C-1 were
provided by Dr. Shen (Bethesda, MD, USA).41 The KB-3-1 derivative
KB-HU selected against hydroxyurea was generously donated by
Dr. Y. C. Cheng (Yale University, NewHaven, CT, USA).35 The ovarian
cancer cell line A2780 and its cisplatin resistant subline A2780/cis were
purchased from Sigma (Bornem, Belgium). The human colon cancer
cell line HCT116 p53 wild-type and its p53/ko clone with deleted
p53 were generously donated by Dr. B. Vogelstein (Johns Hopkins
University, Baltimore, MD, USA).42 The non-small-cell lung cancer cell
model SW1573 with its ABCC1- and LRP-overexpressing subline 2R120
and its ABCB1-overexpressing subline 2R160 is from H. Broxterman
(Department of Medical Oncology, Free University Hospital, Amsterdam,
The Netherlands).43
PBMCs from healthy donors were isolated as previously reported.44
Normal astrocytes from murine origin were established and cultured as
previously described.45
Cells were grown in RPMI 1640 (BioWhittaker, Lonza, Verviers,
Belgium) supplemented with 10% heat-inactivated fetal calf serum
(BioWhittaker) and 1% antibiotic−antimycotic (BioWhittaker) at 37 °C
in humid atmosphere and 5% CO2. PBMC viability was evaluated as
previously described.44
1 (Sigma), 2 (Santa Cruz Biotechnology, Heidelberg, Germany), 3
(Sigma), 4 (Enzo Life Sciences, Antwerpen, Belgium), 38 (Cayman,
Bio-connect, Huissen, The Netherlands), and all 2,2-dimethylchro-
mans-related compounds were dissolved in DMSO.
Quantitative Videomicroscopy. For videomicroscopic evaluation
of the in vitro anticancer eﬀects of 18, cells were cultured in 25 cm2
ﬂasks. Time-lapse acquisition of phase contrast microscopy pictures
was automatically recorded every 4 min over a 72 h period in trip-
licate.30,46−48 Quantitative data have been obtained by the counting
of the number of cells on the pictures over time as previously
described30,46,48 and detailed in the legends of the ﬁgures.
MTT Colorimetric Assay. The MTT colorimetric assay was per-
formed as previously described after 72 h of exposure to the com-
pounds.30,46,48 Brieﬂy, cells were seeded in 96-well plates 24 h before
treatments. Concentrations of the compounds tested range from 0.01 to
100 μM for 72 h. The growth inhibitory concentration, i.e., the GI50 is
the concentration of a compound that decreased by 50% the optical
density in comparison to the untreated control condition. Experiments
on Hs683, T98G, and U373 cells were conducted once in sextuplicate.
Cell Cycle Analysis. Cell cycle distribution was analyzed as pre-
viously described.32
SA-β-gal Assay.The assessment of senescence was performed using
an SA-β-gal assay described elsewhere.32
Monitoring Cell Proliferation in SIRT1- or SIRT2-Depleted
Cells. Cells in 12-well plates were transfected with small interfer-
ing RNAs [siRNAs; Qiagen, Venlo, The Netherlands: SiSIRT1_1
(SI00098434), SiHDAC1_2 (SI00098448), siSIRT2_1 (SI00098406),
siSIRT2_2 (SI02655471), control siRNA (AllStars Negative Control
siRNA)] as described elsewhere.49 Gene silencing eﬀects on glioblas-
toma cell proliferation were recorded and quantiﬁed by time-lapse phase
contrast videomicroscopy using IncuCyte live-cell imaging system
(Essen Bioscience Inc., Hertfordshire, U.K.).
Generation of U373 and Hs683 Spheroids. Spheroids were
generated as previously described elsewhere49 using a starting cell sus-
pension of 1 × 103 cells in 25 μL. The volume of multicellular spheroids
expressed in voxels (3D pixels) was determined through the generation
of 3D plots using the ReViSP software after an initial segmentation with
ImageJ software (U.S. National Institutes of Health, Bethesda, MD,
USA) as described elsewhere.50
ATP Measurement in 3D Spheroid Culture. ATP levels were
measured using the CellTiter-Glo 3D cell viability assay (Promega,
Leiden, The Netherlands) according to the manufacturer’s instructions.
Brieﬂy, spheroids were harvested and then mixed with CellTiter-Glo 3D
reagent. After shaking for 5 min and stabilizing for 25 min, luminescence
signal was measured with a luminometer (Centro LB 960, Berthold
Technologies, Korea).
Zebraﬁsh Assay. Wild type zebraﬁsh (Danio rerio) were obtained
from the Zebraﬁsh International Resource Center (ZIRC, University of
Oregon, OR), maintained according to SNU guidelines at 28.5 °C with
10 h dark/14 h light cycles. Zebraﬁsh experiments were carried out as
previously described51 except that cells were ﬂuorescently labeled with
CM-Dil (Invitrogen, Korea) 2 h prior to injection. For CM-Dil labeled
cancer cell injection, micropipettes for injection and anesthesia were
generated from a 1.0 mm glass capillary (World Precision Instruments,
Sarasota, FL, USA) by using a micropipette puller (Shutter Instrument,
Novato, CA, USA). 48 h after fertilization, zebraﬁsh were anesthetized in
0.02% tricaine (Sigma) and immobilized on an agar plate. 100−200 of
CM-Dil labeled cancer cells are also stained with 0.05% of phenol red
solution (Sigma) for better visualization during injection into the yolk
sac. After injection, zebraﬁsh were incubated in 24-well plates containing
Danieau solution with 0.003% phenylthiourea (Sigma, USA) at 28.5 °C
for 72 h. Pictures were taken by ﬁxing zebraﬁsh embryos onto a glass
slide with 3% methylcellulose (Sigma).
In Vitro HDAC Activity Assay. Assays were carried out as pre-
viously described.52,53 IC50 values were determined using the GraphPad
Prism 6.0 software.
Western Blot Analysis. For the preparation of total proteins, cells
were harvested, washed in cold 1× PBS, and lysed in MPER (Thermo-
Scientiﬁc, Erembodegem-Aalst, Belgium) supplementedwith 1× protease
inhibitor cocktail (Complete EDTA-free, Roche, Prophac, Luxembourg,
Luxembourg) according to the manufacturer’s instructions. Histones
were isolated as previously reported.54
Western blots were carried out as previously described.55 Antibodies
were from the following: from Sigma, anti-β-actin (A5441); from Santa
Cruz Biotechnology (Heidelberg, Germany), antiacetylated α-tubulin
(sc-23950), anti-SIRT1 (sc-15404), anti-SIRT2 (sc-20966); from Merck
Millipore (Brussels, Belgium), anti-histone H1 (05-457), anti-histone H4
(05-858), anti-acetylated histoneH4 (06-866), anti-acetylated histoneH3
lysine 56 (04-1135); from Calbiochem, anti-tubulin (CP06); and the
corresponding secondary antibody (all from Santa Cruz Biotechnol-
ogy). β-Actin or α-tubulin and histone H1 or Coomassie blue staining
(LKB, Villeneuve-la-Garenne, France) were used as loading controls for
non-histone and histone proteins, respectively. Western blot mem-
branes and Coomassie blue gels were quantiﬁed using ImageQuant TL
(GE Healthcare, Roosendaal, The Netherlands) and ImageJ (U.S.
National Institutes of Health, Bethesda, MD, USA) software, respec-
tively, and data were reported to the control.
Statistical Analyses. Statistical analyses were carried out using the
GraphPad Prism 6.0 software. One-way ANOVA and the Holm−Sidak
multiple comparison tests were used for statistical comparisons. p values
below 0.05 were considered as statistically signiﬁcant.
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